Systematic review with meta-analysis: Non-invasive assessment of non-alcoholic fatty liver disease - The role of transient elastography and plasma cytokeratin-18 fragments

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 3, 2014, Pages 254-269

  Kwok, R ^a,b   Tse, Y K ^a,c   Wong, G L H ^a,c   Ha, Y ^d   Lee, A U ^b   Ngu, M C ^b   Chan, H L Y ^a,c   Wong, V W S ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CXCL2 CHEMOKINE; CYTOKERATIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ELASTOGRAPHY; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; VALIDITY;

BIOLOGICAL MARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HUMANS; KERATIN-18; LIVER CIRRHOSIS; OBESITY; SENSITIVITY AND SPECIFICITY;

EID: 84891889855     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12569     Document Type: Review

References (117)

1. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
2. Wong VW, Chu WC, Wong GL, et al,. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-15.
3. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
4. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN,. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
5. Bhala N, Angulo P, van der Poorten D, et al,. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-16.
6. Wong VW, Wong GL, Choi PC, et al,. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
7. Festi D, Schiumerini R, Marzi L, et al,. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400.
8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR,. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
9. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
10. Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G,. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol 2010; 24: 661-70.
11. Gaia S, Carenzi S, Barilli AL, et al,. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71.
12. Wong VW-S, Vergniol J, Wong GL-H, et al,. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862-71.
13. Lupsor M, Badea R, Stefanescu H, et al,. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointest Liver Dis 2010; 19: 53-60.
14. Wong VW-S, Vergniol J, Wong GL-H, et al,. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
15. Yoneda M, Suzuki K, Kato S, et al,. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-7.
16. Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A,. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60.
17. Kumar R, Rastogi A, Sharma MK, et al,. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013; 58: 265-74.
18. Yoneda M, Yoneda M, Mawatari H, et al,. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.
19. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE,. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
20. Yilmaz Y, Dolar E, Ulukaya E, et al,. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-44.
21. Diab DL, Yerian L, Schauer P, et al,. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008; 6: 1249-54.
22. Younossi ZM, Jarrar M, Nugent C, et al,. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-7.
23. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ,. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
24. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al,. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease. J Clin Gastroenterol 2010; 44: e87-95.
25. Musso G, Cassader M, De Michieli F, Saba F, Bo S, Gambino R,. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 2011; 94: 1033-42.
26. Joka D, Wahl K, Moeller S, et al,. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55: 455-64.
27. Papatheodoridis M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A,. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol 2012; 63: 347-53.
28. Pirvulescu I, Gheorghe L, Csiki I, et al,. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery. Chirurgia (Bucur) 2012; 107: 772-9.
29. Shen J, Chan HL, Wong GL, et al,. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012; 56: 1363-70.
30. Palmeri ML, Wang MH, Rouze NC, et al,. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666-72.
31. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J,. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
32. Reitsma JBGA, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH,. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-90.
33. Rutter CMGC,. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001; 20: 2865-84.
34. Metandi HR,. Stata Module for Meta-analysis of Diagnostic Accuracy. Department of Economics: Statistical Software Components. Boston College, 2008.
35. Review Manager (RevMan) The Cochrane Collaboration. 5.0th ed. Copenhagen: The Nordic Cochrane Centre, 2008.
36. Younossi ZM, Stepanova M, Rafiq N, et al,. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-82.
37. Ekstedt M, Franzen LE, Mathiesen UL, et al,. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
38. Pais R, Charlotte F, Fedchuk L, et al,. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59: 550-6.
39. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K,. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-9.
40. Tamimi TI, Elgouhari HM, Alkhouri N, et al,. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011; 54: 1224-9.
41. Abiru S, Migita K, Maeda Y, et al,. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
42. Copaci I, Micu L, Voiculescu M,. The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointest Liver Dis 2006; 15: 363-73.
43. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG,. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
44. Wong VW, Hui AY, Tsang SW, et al,. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1154-61.
45. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE,. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-9.
46. Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A,. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol 2012; 63: 347-53.
47. Jarrar MH, Baranova A, Collantes R, et al,. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-21.
48. Haukeland JW, Damas JK, Konopski Z, et al,. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-74.
49. Chitturi S, Abeygunasekera S, Farrell GC, et al,. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
50. Boza C, Riquelme A, Ibanez L, et al,. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-53.
51. Yoneda M, Mawatari H, Fujita K, et al,. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-82.
52. Hui JM, Farrell GC, Kench JG, George J,. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004; 39: 1458-9.
53. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E,. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1310-21.
54. Kirovski G, Dorn C, Huber H, et al,. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. Exp Mol Pathol 2011; 91: 780-3.
55. Yoneda M, Uchiyama T, Kato S, et al,. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008; 8: 53.
56. Tarcin O, Gedik N, Karakoyun B, et al,. Serum prolidase and IGF-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats. Dig Dis Sci 2008; 53: 1938-45.
57. Kayadibi H, Gultepe M, Yasar B, et al,. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2009; 54: 1764-71.
58. Basta G, Sironi AM, Lazzerini G, et al,. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-34.
59. Geroldi D, Falcone C, Emanuele E, et al,. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23: 1725-9.
60. Yilmaz Y, Ulukaya E, Gul OO, et al,. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009; 42: 802-7.
61. Geroldi D, Falcone C, Emanuele E,. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-8.
62. Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR,. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem 2011; 44: 1375-9.
63. Rensen SS, Slaats Y, Nijhuis J, et al,. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol 2009; 175: 1473-82.
64. Horoz M, Bolukbas C, Bolukbas FF, et al,. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005; 5: 35.
65. Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T,. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther 2006; 23: 91-8.
66. Lomonaco R, Sunny NE, Bril F, Cusi K,. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013; 73: 1-14.
67. Cheung O, Kapoor A, Puri P, et al,. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46: 1091-100.
68. Nomura K, Yano E, Shinozaki T, Tagawa K,. Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups. J Occup Health 2004; 46: 423-8.
69. Poynard T, Ratziu V, Charlotte F, et al,. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34.
70. Lassailly G, Caiazzo R, Hollebecque A, et al,. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011; 23: 499-506.
71. Younossi ZM, Page S, Rafiq N, et al,. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21: 431-9.
72. Anty R, Iannelli A, Patouraux S, et al,. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32: 1315-22.
73. Feldstein AE, Lopez R, Tamimi TA, et al,. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010; 51: 3046-54.
74. Roskams T, Yang SQ, Koteish A, et al,. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003; 163: 1301-11.
75. Dixon JB, Bhathal PS, O'Brien PE,. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
76. Paradis V, Zalinski S, Chelbi E, et al,. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-9.
77. Yasui K, Hashimoto E, Komorizono Y, et al,. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-33.
78. Wong VW, Wong GL, Tsang SW, et al,. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009; 29: 387-96.
79. Hui AY, Wong VW, Chan HL, et al,. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407-13.
80. Poonawala A, Nair SP, Thuluvath PJ,. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-92.
81. Struben VM, Hespenheide EE, Caldwell SH,. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 9-13.
82. Angulo P, Hui JM, Marchesini G, et al,. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
83. Wong VW, Wong GL, Chim AM, et al,. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103: 1682-8.
84. Angulo P, Bugianesi E, Bjornsson ES, et al,. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: e4.
85. Kim D, Kim WR, Kim HJ, Therneau TM,. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-65.
86. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP,. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9.
87. Shah AG, Lydecker A, Murray K, et al,. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
88. Mehta SH, Lau B, Afdhal NH, Thomas DL,. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
89. Hernaez R, Lazo M, Bonekamp S, et al,. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.
90. Saadeh S, Younossi ZM, Remer EM, et al,. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
91. Osawa H, Mori Y,. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996; 24: 25-9.
92. Ballestri S, Lonardo A, Romagnoli D, et al,. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012; 32: 1242-52.
93. Park SH, Kim PN, Kim KW, et al,. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-12.
94. Rofsky NM, Fleishaker H,. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995; 16: 16-33.
95. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F,. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
96. Fishbein M, Castro F, Cheruku S, et al,. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39: 619-25.
97. McPherson S, Jonsson JR, Cowin GJ, et al,. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009; 51: 389-97.
98. Machado MV, Cortez-Pinto H,. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007-19.
99. Yin M, Talwalkar JA, Glaser KJ, et al,. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: e2.
100. Huwart L, Sempoux C, Vicaut E, et al,. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32-40.
101. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL,. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.
102. Castera L, Foucher J, Bernard PH, et al,. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.
103. Wong GL, Wong VW, Chim AM, et al,. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011; 26: 300-5.
104. Friedrich-Rust M, Hadji-Hosseini H, Kriener S, et al,. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol 2010; 20: 2390-6.
105. Myers RP, Pomier-Layrargues G, Kirsch R, et al,. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
106. Osaki A, Kubota T, Suda T, et al,. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World J Gastroenterol 2010; 16: 2918-25.
107. Friedrich-Rust M, Romen D, Vermehren J, et al,. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-31.
108. Friedrich-Rust M, Nierhoff J, Lupsor M, et al,. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19: e212-9.
109. Masuda K, Ono M, Fukumoto M, et al,. Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. Hepatol Res 2012; 42: 273-9.
110. Kikuchi M, Tomita K, Nakahara T, et al,. Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis. Scand J Gastroenterol 2009; 44: 229-36.
111. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA,. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
112. Cales P, Laine F, Boursier J, et al,. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-73.
113. Sheth SG, Flamm SL, Gordon FD, Chopra S,. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
114. Wai C-T, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
115. Guha IN, Parkes J, Roderick P, et al,. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 2008; 47: 455-60.
116. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
117. Ratziu V, Massard J, Charlotte F, et al,. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.